,18,19 One future step could also be the enrichment of prognostic algorithms with molecular tumor features, such as the presence of the shorter and more oncogenic EML4-ALK fusion variant 3, which has been associated with earlier intracranial progression in TKI-treated ALK+ NSCLC.10 The gene discussed is ALK; the disease is non-small cell lung carcinoma.